Overview of HGH Fragment 176-191
HGH Fragment 176-191 is a synthetic peptide consisting of amino acids 176-191 from the C-terminal region of human growth hormone. This 16-amino acid sequence represents the specific portion of hGH that researchers have identified as responsible for lipolytic activity in laboratory models. The fragment maintains the fat-metabolising properties of the parent hormone while eliminating growth-promoting effects, making it a valuable tool for investigating metabolic pathways in controlled research environments. Scientists at Stroid UK Shop utilise this peptide to examine cellular energy expenditure and adipocyte metabolism in laboratory settings.
Laboratory Research Applications
Research teams investigate HGH Fragment 176-191 primarily for its selective effects on adipose tissue metabolism. In cell culture studies, this peptide demonstrates the ability to stimulate lipolysis without activating growth hormone receptors linked to anabolic processes. Laboratory investigations focus on its mechanism of action through beta-3 adrenergic receptor pathways and its role in activating hormone-sensitive lipase. Researchers studying metabolic disorders frequently examine this fragment alongside other compounds from our comprehensive peptides collection to understand synergistic effects on cellular metabolism. The fragment’s selectivity makes it particularly useful for comparative studies with full-length growth hormone preparations.
Technical Specifications
| Parameter | Specification |
|---|---|
| Molecular Weight | 1815.08 g/mol |
| Amino Acid Sequence | 16-amino acid C-terminal fragment |
| Purity | ≥98% by HPLC |
| Appearance | White lyophilised powder |
| Storage Temperature | -20°C (lyophilised), 2-8°C (reconstituted) |
| Solubility | Water soluble |
| CAS Number | Verify with supplier |
| Half-life | Approximately 30 minutes in vitro |
Laboratory investigators often compare this fragment with related growth hormone derivatives available through our Fragment 176-191 category to evaluate structure-activity relationships in metabolic research.
Research Compliance Statement
HGH Fragment 176-191 is manufactured exclusively for in-vitro laboratory research applications and is not intended for human consumption, therapeutic use, or any clinical applications. Research institutions must maintain appropriate biosafety protocols when handling this peptide and ensure compliance with local regulations governing research chemical use. Investigators should verify the compound’s suitability for their specific research methodology and maintain proper documentation of experimental procedures. This product joins other research tools in our SARMs collection as part of our comprehensive catalogue designed to support legitimate scientific investigation into metabolic and endocrine pathways.
